Trial Profile

A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NBE 002 (Primary)
Indications Advanced breast cancer; Carcinoma; Lung cancer; Lymphoma; Sarcoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors NBE-Therapeutics

Most Recent Events

04 Sep 2023 Status changed to discontinued, according to ClinicalTrials.gov: US National Institutes of Health.
07 Dec 2022 Status changed from recruiting to active, no longer recruiting.
09 Nov 2021 Planned End Date changed from 1 Jul 2023 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com